Breaking Finance News

GlaxoSmithKline PLC (LON:GSK) target price held steady at 1,800.00GBX, reported today by Goldman Sachs

Displaying a price of 1,624.50GBX, GlaxoSmithKline PLC (LON:GSK) traded 0.70% lower on the day. The last stock close is up 6.92% from the two hundred day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same period. GSK has recorded a 50-day average of 1,656.11GBX and 200-day average of 1,528.28GBX. Trade volume was was down over the average, with 1,326,118 shares of GSK changing hands under the typical 8,772,160 shares.

Indicating a possible upside of 0.11%, Goldman Sachs held the price target of GlaxoSmithKline PLC (LON:GSK) at 1,800GBX

Recent Performance Graph:

GlaxoSmithKline PLC (LON:GSK)

A total of 24 analysts have issued a research note on the company. Three analysts rate the stock a strong buy, six firms rate the company a buy, 17 firms rate the stock a hold, two analysts rate the company to underperform, and lastly 0 analystsrate the stock as sell with an average target price of 1,577.33GBX

GlaxoSmithKline PLC has a 52 week low of 1,227.50GBX and a one-year high of 1,716.50GBX with a PE ratio of 2,723 and has a market capitalization of 0.0 GBX.

Brief Synopsis On GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, and respiratory and rare diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.